<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239469</url>
  </required_header>
  <id_info>
    <org_study_id>PC003DT</org_study_id>
    <nct_id>NCT04239469</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.</brief_title>
  <official_title>Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knop Laboratorios</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Knop Laboratorios</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blind randomized placebo controlled trial in 44 women with fibromyalgia and
      persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the
      city of Valparaiso. Patients will be randomized to either placebo or active principle and be
      followed for 3 months. Assesment of efficacy and safety will be done by measurement of
      changes in their Fibromyalgia Impact Questionnaire (FIQ) score, Insomnia Severity Index (ISI)
      score, pain Visual Analogue Scale (VAS) score, plasma cytokine levels and detection of
      adverse effects.

      The active principle will be a standardized extract of cannabis sativa containing 1 milligram
      of tetrahydrocannabinol (THC) and 0.45 milligrams cannabidiol (CBD) per drop.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fibromyalgia Impact Questionnaire (FIQ) score</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 104 and higher values indicating worse symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fibromyalgia Impact Questionnaire (FIQ) score</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 104 and higher values indicating worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibromyalgia Impact Questionnaire (FIQ) score</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 104 and higher values indicating worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibromyalgia Impact Questionnaire (FIQ) score</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 104 and higher values indicating worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index (ISI) score</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 28 and higher scores indicating worse insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index (ISI) score</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 28 and higher scores indicating worse insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index (ISI) score</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 28 and higher scores indicating worse insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index (ISI) score</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Numeric score validated in its spanish version, with scores ranging from 0 to 28 and higher scores indicating worse insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain Visual Analog Scale (VAS) score</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Numeric visual analog scale, with scores ranging from 0 to 10 and higher scores indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain Visual Analog Scale (VAS) score</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Numeric visual analog scale, with scores ranging from 0 to 10 and higher scores indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain Visual Analog Scale (VAS) score</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Numeric visual analog scale, with scores ranging from 0 to 10 and higher scores indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain Visual Analog Scale (VAS) score</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Numeric visual analog scale, with scores ranging from 0 to 10 and higher scores indicating worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma cytokines</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Quantitative ELISA measurements of plasma levels of IL-6, IL-8, CXCL5, CXCL6, MCP-2, LAP TGFβ-1 and TNFα</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Cannabis</condition>
  <arm_group>
    <arm_group_label>KL16-012</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will use a liquid standardized extract of cannabis sativa. Each drop will contain 1 mg of THC and 0.45 mg of CBD. Administration will be sublingual, while dosing will begin at 3 drops per day and be escalated to 15 drops per day by week 5 according to an escalation chart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will use a liquid placebo identical to the active principle in both appearance and taste.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL16-012</intervention_name>
    <description>Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD</description>
    <arm_group_label>KL16-012</arm_group_label>
    <other_name>Cannabiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of fibromyalgia based on ACR 2010 criteria

          -  FIQ &gt; 39 (refractary symptoms)

          -  Previous use of at least 2 conventional pharmacotherapies

        Exclusion Criteria:

          -  History of substance use disorder

          -  History of major psychiatric or cardiovascular diseases

          -  Pregnancy

          -  Urine THC (+)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>phytocannabinoids</keyword>
  <keyword>cannabinoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

